Evidence map›Paper›PMID 25121353›Full record

ArticleThe Biochemical journal2014

A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition.

Yong Fang, Yihong Wang, Yulei Wang, Yan Meng, Junlan Zhu, Honglei Jin, Jingxia Li, Dongyun Zhang, Yonghui Yu, Xue-Ru Wu and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Biochemical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. TPC Functions in the Immune System.Handbook of experimental pharmacology · 2023
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. ATG7 Promotes Bladder Cancer Invasion via Autophagy-Mediated Increased ARHGDIB mRNA Stability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yong Fang
Yihong Wang‡Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China.
Yulei Wang†Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, U.S.A.
Yan Meng†Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, U.S.A.
Junlan Zhu†Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, U.S.A.
Honglei Jin†Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, U.S.A.
Jingxia Li†Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, U.S.A.
Dongyun Zhang†Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, U.S.A.
Yonghui Yu†Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, U.S.A.
Xue-Ru Wu
Chuanshu Huang†Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, NY 10987, U.S.A.
Zhejiang University · CN

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
Reagent/Service CoreP01CA165980 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WU, XUE-RU · 2013 to 2023
$13.5M
Molecular Mechanisms of Nickel-Induced TumorigenicityR01CA112557 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUANG, CHUANSHU · 2004 to 2016
$2.9M
Mechanisms underlying therapeutic effect of a new compound Isorhapontigenin (ISO)R01CA177665 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUANG, CHUANSHU · 2013 to 2018
$1.7M
Molecular and Genetic Studies of Bladder TumorigenesisI01BX002049 · VA · VA NEW YORK HARBOR HLTHCARE/SYS/BROOKLYN · PI WU, XUE-RU · 2014 to 2022
–
BLRD VA I01 BX002049NCI NIH HHS CA112557NCI NIH HHS CA165980NCI NIH HHS CA177665NCI NIH HHS P01 CA165980NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA112557NCI NIH HHS R01 CA177665
6 · The paper itself

Abstract

p27Kip1 is a potent inhibitor of cyclin-dependent kinases that drive G1-to-S cell-cycle transition. Reduced p27Kip1 expression is prevalent in a wide range of human tumours; however, the exact mechanism(s) of p27Kip1-mediated tumour suppression remains obscure. In the present study, we identified a close inverse relationship between p27Kip1 and EGFR (epidermal growth factor receptor) expression: the parental T24 human bladder cancer cells had high p27Kip1 expression but low EGFR expression and, in striking contrast, the metastatic derivative of T24 (T24T) had low p27Kip1 expression but high EGFR expression. This relationship was also found in various human cancer tissues, and was not only just correlative but also causal; depletion of p27Kip1 in MEF (mouse embryonic fibroblast) cells resulted in markedly elevated EGFR expression, a result reproducible with an Egfr promoter-luciferase reporter in both T24 and MEF cells, suggesting transcriptional repression of EGFR by p27Kip1. Indeed, p27Kip1 was found to regulate EGFR expression via the JNK (c-Jun N-terminal kinase)/c-Jun transcription factor: p27Kip1 deficiency activated JNK/c-Jun, whereas inhibition of JNK/c-Jun by dominant-negative mutants dramatically repressed Egfr transcription. Furthermore, the proximal promoter of the Egfr gene was crucial for its transcription, where the recruiting activity of c-Jun was much greater in p27Kip1-/- cells than in p27Kip1+/+ cells. Introduction of GFP-p27Kip1 into T24T cells suppressed JNK/c-Jun activation, EGFR expression and anchorage-independent growth. The results of the present study demonstrate that p27Kip1 suppresses JNK/c-Jun activation and EGFR expression in MEFs and human bladder cancer cells, and the results obtained are consistent with those from human cancer specimens. The present study provides new insights into p27Kip1 suppression of cancer cell growth, migration and metastasis.

Indexed as

AdenocarcinomaAdenocarcinoma of LungAdultAgedAnimalsCell LineCell Line, TumorCell ProliferationColonic NeoplasmsCyclin-Dependent Kinase Inhibitor p27Down-RegulationErbB ReceptorsFemaleFibroblastsGene Knockout TechniquesHumansCDKN1B protein, humanCyclin-Dependent Kinase Inhibitor p27EGFR protein, humanErbB ReceptorsJNK Mitogen-Activated Protein KinasesProto-Oncogene Proteins c-jun

Identifiers

PMID25121353
PMCPMC4209780
OpenAlexW2160994454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.